Cybin Inc. (NYSE-A:CYBN, NEO:CYBN) CEO Doug Drysdale takes Proactive's Stephen Gunnion through the biopharmaceutical company's two major development programs - CYB003 and CYB004 - as it makes positive progress towards its goal of advancing psychedelics to therapeutics.
Drysdale telling Proactive that the company has now moved from the lab to the clinic where the programs are underway.
"Going from the bench to the clinic in 18 months is pretty fantastic," Drysdale said. "That's the benefit of working with molecules that we know an awful lot about already as it derisks development programs and reduces the cost of them."